A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
58actual
Sites
21
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-13 | actual | When the study began enrolling |
| Primary completion | 2026-07-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma (HCC)
Interventions
- Drug: Durvalumab — also filed as MEDI4736, IMFINZI
- Drug: Bevacizumab — also filed as AVASTIN, ZIRABEV
- Procedure: Transarterial Radioembolization (TARE) — also filed as TheraSphere
Primary outcome
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured From Day 1 until date of progressive disease or death [Approximately 3 years]
Publications
- PMID 41903993 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed